Optimal management of steroid-dependent ulcerative colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease with variable disease severity and treatment response.
• Corticosteroids (CSs) are effective for inducing remission but not for maintenance due to side effects.
• CS-free remission is a key endpoint in evaluating UC therapies.

Purpose of the Study:

• To review and synthesize data on the efficacy of various medications for achieving corticosteroid-free remission in active ulcerative colitis.
• To provide a synopsis of current research on therapeutic agents for UC remission maintenance.

Main Methods:

• Literature review of studies evaluating medications for CS-free remission in active UC.
• Individual efficacy assessment of established agents (thiopurines, methotrexate, infliximab, adalimumab, vedolizumab, golimumab) and newer experimental agents.
• Consideration of colectomy as a last resort.

Main Results:

• The review synthesizes findings on the effectiveness of multiple drug classes in achieving and maintaining UC remission without corticosteroids.
• Efficacy data for thiopurines, methotrexate, and various biologics (infliximab, adalimumab, vedolizumab, golimumab) are individually evaluated.
• The role of newer experimental agents in achieving CS-free remission is discussed.

Conclusions:

• CS-free remission is an important goal in ulcerative colitis management.
• Several established and emerging therapies demonstrate potential for achieving CS-free remission.
• Further research is needed to optimize treatment strategies for long-term UC remission without corticosteroids.